BioInvent International (Sweden) Profile

SEK 0.04  2.11%

BioInvent International Summary

BioInvent International AB (BINV) is traded on Stockholm Stock Exchange in Sweden. It is located in The Gamma Building and employs 56 people. The company currently falls under 'Small-Cap' category with current market capitalization of 588.67 M. BioInvent International AB operates under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 304.7 M outstanding shares. BIOINVENT has accumulated about 133.76 M in cash with (75.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Check BioInvent International Probability Of Bankruptcy

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 66.08%30 days 1.86  about 33.85%
Based on normal probability distribution, the odds of BioInvent International to move above current price in 30 days from now is about 33.85% (This BioInvent International AB probability density function shows the probability of BioInvent International Stock to fall within a particular range of prices over 30 days) .

BioInvent International Risk Profiles

Key Fundamentals

BioInvent International Against Markets

Current Ratings

BioInvent International 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 89% 
Equity ratings for BioInvent International AB are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
BioInvent International AB , a research-based pharmaceutical company, focuses on the discovery and development of antibody-based drugs against cancer. The Company was founded in 1997 and is based in Lund, Sweden. BioInvent International operates under Biotechnology classification in Sweden and traded on Stockholm Stock Exchange. It employs 56 people. more
NameBioInvent International AB
President CEOMichael OredssonView All
Macroaxis Advice
Healthcare, Pharmaceuticals And Biosciences
InstrumentSweden Stock View All
Business AddressThe Gamma Building
ExchangeStockholm Stock Exchange
IndustryPharmaceuticals And Biosciences
Contact Number46 4 62 86 85 50
CurrencySEK - Swedish Kronor

Diversify with BioInvent International AB

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BioInvent International AB to your portfolio


BioInvent International Corporate Directors
Jonas Jendi Director
Lars Ingelmark Independent Member of the Board of Directors
Martin Nicklasson Director
Check also Trending Equities. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.